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Evaluation of Immunomodulatory Biomarkers in a
Pressure Overload Model of Heart Failure
Barry E. Bleske, Pharm.D., FCCP, Hyun Seok Hwang, M.S., Issam Zineh, Pharm.D., 
Michael G. Ghannam, and Marvin O. Boluyt, Ph.D.
Study Objectives. To characterize the immunomodulatory response in a
pressure overload model of heart failure, and to further validate this animal
model of human heart failure.
Design. Randomized, controlled, animal study.
Setting.  Large university research facility.
Animals. Twenty-seven, male, Sprague-Dawley rats.
Intervention. The rats underwent either aortic constriction or a sham procedure.
Measurements and Main Results. Six months after the surgical procedure,
echocardiographic measurements were obtained, the animals were
sacrificed, and plasma samples were taken to measure concentrations of
biomarkers.  As six (40%) of the 15 rats in the aortic-constriction group
died before the 6 months, only nine rats from this group underwent
immunomodulatory evaluation.  Compared with the sham procedure,
aortic constriction increased the left ventricle:body weight ratio in the rats
(p=0.0016)  It also decreased the velocity of circumferential shortening
(p=0.08) and increased myocardial expression of atrial natriuretic factor, b-
myosin heavy chain, and fibronectin (p<0.05).  Concentrations of the
proinflammatory mediator interleukin (IL)-1b and the counterregulatory
mediator IL-10 also significantly increased (p<0.04) in the group that
underwent aortic constriction compared with the group that underwent the
sham procedure.  Nonsignificant increases (mean change ~50–180%) were
also observed for IL-2, IL-6, and leptin concentrations.
Conclusions.  In this classic animal model of heart failure, a systemic
immunomodulatory response was evaluated after 6 months of pressure
overload resulting in myocardial decompensation and, in some cases,
mortality. The findings are similar to the immunomodulatory response that
may be observed in human heart failure.  These novel results further define
this model of heart failure and suggest another aspect of its relevance to
human heart failure with regard to pressure overload and the immuno-
modulatory response.
Key Words: aortic constriction, heart failure, cytokines, chemokines,
interleukin, leptin, animal study.
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The pathophysiology of heart failure is
complex, and our understanding of its underlying
mechanisms has evolved throughout the years.  A
hemodynamic defect was previously considered
to be the primary cause of heart failure, but this
understanding evolved to include a neuro-
hormonal aspect.  Today, the pathophysiologic
model of heart failure has further evolved to
include an immunomodulatory component.1 The
broad spectrum of effects that neurohormones
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have on the myocardium and the mechanisms
that regulate this system in the setting of heart
failure have been extensively studied over the last
20 years.  The mechanisms and models of
immunomodulatory molecules, such as cytokines,
chemokines, and angiogenic factors in heart
failure, have only recently gained notable attention.
Furthermore, a few investigators have simultane-
ously explored a wide range of inflammation-
related proteins as they relate to heart failure.  To
begin to address these issues, we evaluated the
effect of sustained pressure overload on a wide
array of systemic immunomodulatory proteins in
a rat aortic-constriction model of heart failure.
To our knowledge, this is the first time these
variables were measured in this model at this
time point in the progression of heart failure.
Methods
Animals
Male Sprague-Dawley rats were used for all
experiments.  The University Committee on Use
and Care of Animals at the University of
Michigan approved all animal protocols.  The
investigation conformed to the Guide for the
Care and Use of Laboratory Animals published
by the National Institutes of Health (revised in
1996).
Protocol
Six-week-old, male Sprague-Dawley rats
weighing 250–275 g were obtained and maintained
on a cycle of 12 hours of light and 12 hours of
darkness.  They had access to rat chow and water
ad libitum.  After a stabilization period and when
the rats weighed a mean ± SD of 300 ± 10 g, 12
were randomly selected to undergo sham surgery,
and 15 were randomly selected for aortic constriction.
In the rats that survived for 6 months after the
procedures, echocardiographic measurements
were taken, the animals were sacrificed, and
plasma samples were obtained by directly aspi-
rating the myocardium.  Samples were immediately
placed in tubes containing 0.05 ml of 10% disodium
ethylenediaminetetraacetic acid and centrifuged.
The resultant plasma samples was immediately
frozen to -80°C until they were assayed.
Aortic Constriction
Aortic constriction was conducted as described
previously.2 The animals were given pentobarbital
30 mg/kg for anesthesia, and we performed a left
thoracotomy, exposing the ascending aorta.  A
hemoclip was placed around the aorta 4–6 mm
superior to the aortic valve, with the gap of the
hemoclip applicator adjusted to 1.02 mm by
using a thumbscrew.  Previous experiments had
established that a mean ± SD left ventricular–
distal aortic pressure gradient of 46 ± 12 mm Hg
resulted from constriction of this severity.  When
the clip was in place, pleural pressure was rein-
stated, and the wound was closed with coated
polyglactin 910 sutures.  The rats were ambulatory
within 2 hours and were then returned to their
cages.
Northern Blotting
Total RNA was isolated from the left ventricles,
as described previously.3, 4 Complementary DNA
probes were synthesized and radiolabeled from a
template by using the random prime method.
The probes for atrial natriuretic factor and b-
myosin heavy chain, fibronectin, glyceraldehyde
3-phosphate dehydrogenase, and the 18S
ribosomal RNA were described previously.3, 4
Oligonucleotides were radiolabeled by using
terminal deoxynucleotide transferase with [a-
32P]deoxyadenosine 5′-triphosphate.
Measurement of Cytokines, Chemokines, and
Angiogenic Factor
We evaluated immunoproteins that might
plausibly contribute to the pathophysiology of
heart failure (proinflammatory mediators) or to
protection against it (antiinflammatory mediators).
These proteins were chemokines (eotaxin, monocyte
chemotactic protein-1, macrophage inflammatory
protein-1a, and interferon-g–inducible protein-
10), angiogenic and colony-stimulating factors
(granulocyte and granulocyte-macrophage
colony-stimulating factors and vascular endothe-
lial growth factor), and prototypical proinflam-
matory and antiinflammatory cytokines (inter-
feron-g, interleukin (IL)-1a, IL-1b, IL-2, IL-4,
IL-5, IL-6, IL-9, IL-10, IL-13, IL-17, IL-18, tumor
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necrosis factor-a, and leptin).
All analytes were measured by means of
multiplex immunofluorescence cytometry (100
IS; Luminex Corp., Austin, TX) by using a
commercially available kit (Lincoplex rat
cytokine-chemokine immunoassay panel; Linco
Research, Inc., St. Charles, MO).  All plasma
samples were assayed in duplicate and analyzed
with analysis software (BeadView, version 1;
Upstate, Charlottesville, VA).
Data and Statistical Analysis
Data are reported as medians and interquartile
ranges unless otherwise noted.  To make mean-
ingful comparisons between the sham and aortic-
constriction groups, we analyzed only those
biomarkers for which at least 75% of the samples
had concentrations above the lower limit of
detection.  For these analytes, samples with
undetectable levels were treated as 0 pg/ml.  On
the basis of the 75% cutoff criterion, we excluded
granulocyte colony-stimulating factor, granulocyte-
macrophage colony-stimulating factor, IL-5, IL-
17, macrophage inflammatory protein-1a, tumor
necrosis factor-a, and vascular endothelial
growth factor from the analysis.
Because of the known nonnormal distribution
of immunomarker concentrations, the Kruskal-
Wallis test was used to compare differences in
biomarker concentrations between the sham and
aortic-constriction groups.  A nonpaired t test
was used to evaluate echocardiographic parameters
and gene expression.  A Fisher exact test was used
to evaluate mortality. A p value less than 0.05 was
considered to indicate a statistically significant
difference.
All statistical analyses were performed with
SPSS software, version 11.0 (SPSS Inc., Chicago,
IL).
Results
By the end of the 6 months of pressure overload,
six (40%) of 15 rats in the aortic-constriction
group had died compared with none in the sham
group (p=0.017).  Therefore, immunomodulatory
response was evaluated in only nine rats in the
aortic-constriction group and in all 12 rats from
the sham group.
Expression of the fetal-neonatal genes for atrial
natriuretic factor and the b-myosin heavy chain,
which are considered markers for pathologic
hypertrophy and heart failure, was significantly
elevated in the left ventricle of the rats with
aortic constriction (Figure 1).  Expression of
fibronectin, a component of the extracellular
matrix associated with myocardial fibrosis in
heart failure, was also significantly elevated in the
aortic-constriction group (Figure 2).4 Aortic
constriction produced a 51% increase in the left
ventricle:body weight ratio (p=0.0016; Table 1)
and decreased the velocity of circumferential
shortening by 28% compared with the sham
procedure (p=0.08).  These findings were
expected and demonstrated the progression of
heart failure.
For most analytes, we observed no significant
differences in plasma concentrations between the
sham and aortic-constriction groups (Table 2).
However, mean changes of approximately 50% to
180% were observed for IL-2, IL-6, and leptin.
Significant differences were demonstrated between
the groups for the prototypical proinflammatory
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Figure 1. Expression of fetal-neonatal genes atrial natriuretic factor (ANF) and b-myosin heavy chain (b-MHC), which are
considered markers for pathologic hypertrophy and heart failure, in the left ventricle of rats 6 months after sham or aortic-
constriction (AC) procedure.  A representative northern blot is shown (panel A).  Panel B is a bar graph of the ANF messenger
RNA (mRNA):18S ratios (mean ± standard error) for the sham and the aortic-constriction groups.  Panel C is a bar graph of the
b-MHC mRNA:GAPDH ratios (mean ± standard error) for the two groups.  GAPDH = glyceraldehyde 3-phosphate
dehydrogenase; 18S = 18S ribosomal RNA.  *p<0.05.
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IL-1b (Figure 3) and for the largely antiinflam-
matory IL-10 (Figure 4).  Concentrations of IL-
1b in the sham and aortic-constriction groups
were 18 pg/ml (interquartile range 3–40 pg/ml)
and 68 pg/ml (interquartile range 24–111 pg/ml),
respectively (p=0.039).  In addition, IL-10
concentrations were 4-fold higher in the aortic-
constriction group than in the sham group (596
vs 146 pg/ml, respective interquartile ranges
398–904 vs 0–385 pg/ml, p=0.038).
Discussion
In this exploratory evaluation of the 6-month
immunomodulatory response to aortic constriction,
levels of the proinflammatory mediator IL-1b and
the generally antiinflam-matory molecule IL-10
were elevated in animals exposed to cardiac-
pressure overload compared with controls.  These
findings suggest that this classic model of aortic
constriction not only produced the expected struc-
tural and functional changes in the myocardium
due to pressure overload but also upregulated the
immune system.  The finding that levels of
inflammation-related proteins increased helps to
further define this important animal model and
can direct further research efforts.
The major focus of research regarding the
pathophysiology of heart failure has centered on
neurohormonal activation (e.g., norepinephrine,
angiotensin II) and, to a lesser extent, inflam-
matory proteins such as tumor necrosis factor-a
and IL-6.  However, levels of other immunomodu-
latory mediators have also been found to be
elevated in heart failure and are now considered
important to the development and progression of
507
Table 1.  Biometric Data for the 21 Rats That Survived 6
Months After Surgery
Aortic-
Sham Constriction
Group Group
Measure (n=12)a (n=9)a
Final body weight (g) 561 ± 22 555 ± 23
Weight of left
ventricle (mg) 1021 ± 40 1500 ± 77b
Left ventricle:body
weight ratio (mg:g) 1.82 ± 0.06 2.75 ± 0.20b
Data are mean ± standard error.
aThe difference in the numbers of rats who died before 6 months in
the sham (0) and aortic-constriction groups (6) was significant
(p<0.05).
bThe difference between groups was significant (p<0.05).
Figure 2. Expression of the extracellular matrix gene fibronectin (FN) in the left
ventricle of rats 6 months after sham or aortic-constriction (AC) procedure.  A
representative northern blot is shown (panel A).  Panel B is a bar graph of the FN
messenger RNA (mRNA):GAPDH ratios (mean ± standard error) for the sham
and the aortic-constriction groups.  GAPDH = glyceraldehyde 3-phosphate
dehydrogenase; 18S = 18S ribosomal RNA.  *p<0.05.
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Table 2.  Cytokine and Chemokine Concentrations 6
Months After Sham and Aortic-Constriction Procedures
Concentration (pg/ml)a
Aortic-Constriction
Marker Sham Group Group
Eotaxin 71 (43–124) 52 (33–85)
Monocyte
chemotactic
protein-1 23 (15–35) 30 (25–34)
Inducible
protein-10 50 (35–87) 49 (31–82)
Interferon-g 184 (96–327) 137 (106–227)
Interleukin-1a 180 (136–377) 206 (129–295)
Interleukin-2 19 (9–41) 53 (16–177)
Interleukin-4 9.1 (3–31) 8.7 (4–25)
Interleukin-6 653 (272–1850) 1030 (272–1080)
Interleukin-9 24 (17.5–35) 36 (18–38)
Interleukin-13 696 (467–1102) 712 (285–897)
Interleukin-18 68 (48–95) 86 (60–289)
Leptin 4405 (2690–8090) 6580 (3070–9840)
Data are median (interquartile range).
aNo significant differences were observed between groups.
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the disease.  These additional mediators include
but are not limited to IL-1b, IL-2, IL-18, and
monocyte chemotactic protein-1.1, 5–8 In addition,
IL-10 may be an important counterregulatory
immunomodulator in heart failure.  A number of
investigators have reported elevated levels of
these mediators in patients with heart failure.9–12
The mechanisms by which these mediators
contribute to the pathophysiology of heart failure
have not been completely elucidated and are
likely to be multifactorial.  For example, immuno-
modulatory mediators may decrease cardiac
contractility by means of a number of different
mechanisms.  Interleukin-1b may decrease
contractility by increasing concentrations of
ceramide and sphingosine, whereas IL-2 and IL-6
may increase concentrations of constitutively
expressed nitric oxide synthase.13–16 Other
mechanisms may include uncoupling of the b-
adrenergic receptor, modulation of the activity of
calcium adenosine triphosphatase in the
sacroplasmic reticulum, and oxidative stress.6, 7, 15,
17, 18 In contrast to these mediators, IL-10 may
have a protective function, which may include
antioxidant effect and downregulation of proinflam-
matory immunomodulatory mediators such as
tumor necrosis factor-a, IL-1, and IL-6.19–21 In
heart failure, IL-10 concentrations may be elevated
in response to an increase in levels of catecholamines,
tumor necrosis factor-a, IL-6, and perhaps to an
increase in the rate of apoptosis.22 The elevation
in IL-10 observed in our study may account for
the low concentrations observed for tumor
necrosis factor-a and IL-6.
Overall, we observed a significant increase in
concentrations of the immunomodulatory media-
tors IL-1b and IL-10 after aortic constriction.
Moderate, nonsignificant increases were also seen
for IL-2, IL-6, and leptin.  Additional samples
would likely have produced statistical signifi-
cance.  These findings suggest that activation of
immunomodulators is important in the model of
heart failure associated with chronic pressure
overload and that they are similar to what has
been observed in human heart failure.
A previous study of the effect of hemodynamic
overload in mice for 6 hours to 35 days demon-
strated somewhat different results.23 The authors
measured levels of IL-1b, IL-6, and tumor
necrosis factor-a and reported acute increases at
the 6 hours after aortic constriction.  However,
the same elevation was not observed at time
points later than this.  Reasons for the difference
between the studies are not certain, but they may
be related to the animal model, to the laboratory
technique, and, perhaps most importantly, to the
time of measurement.  The long duration of our
study may have been a factor, and it might have
been most representative of chronic heart failure.
Our study had a number of important limitations.
One was that we measured plasma concentrations
and not tissue expression.  However, human
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Figure 3. Median concentration of interleukin (IL)-1b in
rats undergoing the sham versus aortic-constriction (AC)
procedure (p=0.039).  The intrabox line represents the
median; the lower and upper box edges represent the 25th
and 75th percentiles, respectively; and the upper and lower
whiskers represent 1.5 box-lengths from the upper and
lower quartiles, respectively, or the maximum-minimum
boundaries (whichever is smaller).
Figure 4. Median concentration of interleukin (IL)-10 in
rats undergoing the sham versus aortic constriction (AC)
procedure (p=0.038).  The intrabox line represents the
median; the lower and upper box edges represent the 25th
and 75th percentiles, respectively; and the upper and lower
whiskers represent 1.5 box-lengths from the upper and
lower quartiles, respectively, or the maximum-minimum
boundaries (whichever is smaller).
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studies have demonstrated elevated circulating
levels of immunomodulators in patients with
heart failure.  Second, because we had limited
numbers of samples and because this was the
first exploration in this area, we applied a robust
approach to determine the immunomodulatory
effect on this commonly used animal model of
heart failure, raising the issue of multiple testing.
In light of this issue, the data should be evaluated
as observational data needing confirmation.
What is important is the overall picture of
relatively large changes in immunomodulatory
mediators in this animal model of heart failure
that parallel findings in human heart failure.
Another issue was that we did not have serial
measurements and could not describe the time
course over which the immunomodulatory
response may contribute to the development of
heart failure.  In theory, this response might be a
major or minor contributor early in the develop-
ment of heart failure, or it might be influential
only late in the course of heart failure when the
mortality rate is high.
Finally, although the immunomodulatory
response is important to human heart failure, the
etiology of heart failure in humans is rarely
isolated to pure pressure overload.  It is multi-
factorial and, at minimum, includes altered gene
expression as well as structural, neurohormonal,
immunomodulatory, and hemodynamic changes.
Therefore, the relevance of human heart failure to
our pressure overload model, which demonstrated
typical structural changes and altered gene expres-
sion, is of concern.  However, our novel results
perhaps suggest increased relevance of this model
to human heart failure now that we have observed
an apparent immunomodulatory response.
Conclusion
This study demonstrated an immunomodulatory
response after long-term aortic constriction in a
rat model of heart failure.  The results suggested
that, in this classic animal model of heart failure,
the immunomodulatory response may be an
important component of the milieu creating the
progressive deterioration of pump function.
These findings help to further define this impor-
tant animal model and may enhance its useful-
ness and applicability in studying heart failure.
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